| Budget Amount *help |
¥194,870,000 (Direct Cost: ¥149,900,000、Indirect Cost: ¥44,970,000)
Fiscal Year 2018: ¥30,290,000 (Direct Cost: ¥23,300,000、Indirect Cost: ¥6,990,000)
Fiscal Year 2017: ¥30,290,000 (Direct Cost: ¥23,300,000、Indirect Cost: ¥6,990,000)
Fiscal Year 2016: ¥32,240,000 (Direct Cost: ¥24,800,000、Indirect Cost: ¥7,440,000)
Fiscal Year 2015: ¥32,240,000 (Direct Cost: ¥24,800,000、Indirect Cost: ¥7,440,000)
Fiscal Year 2014: ¥69,810,000 (Direct Cost: ¥53,700,000、Indirect Cost: ¥16,110,000)
|
|---|
| Outline of Final Research Achievements |
On the basis of our previous identification of genetic mutations, we planned to clarify pathophysiology in myelodysplastic syndromes (MDS) associated with combinations of such mutations. Using next generation sequencing technology and mouse models, we elucidated genetic and biological process of acquiring survival benefit, relating to hematopoietic environment, and initiating secondary leukemia from MDS. Of note, we comprehensively uncovered that such pathogenic process was resulted not from a single genetic event but combination of mutations and that such combination was not random and significantly associated with the order of acquiring each mutation. These findings suggest that clonal expansion in MDS is closely related to various genetic events but specific rules strictly controlled by environmental condition.
|
